Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 5/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508756 | 0.82 | EGFR (0.59) | EGFRGRM4PIK3CATGFBR1ERBB2 | |
| SCHEMBL5440513 | 0.82 | EGFR (0.46) | EGFRGRM4TGFBR1ERBB2ERBB4 | |
| SCHEMBL22803770 | 0.81 | EGFR (0.58) | EGFRGRM4PRKD1PIK3CAPIK3CG | |
| SCHEMBL30302532 | 0.81 | EGFR (0.58) | EGFRGRM4PRKD1PIK3CAPIK3CG | |
| SCHEMBL5447665 | 0.81 | EGFR (0.49) | EGFRGRM4TGFBR1ERBB2ERBB4 | |
| SCHEMBL5445026 | 0.81 | EGFR (0.45) | EGFRGRM4TGFBR1ERBB2ERBB4 | |
| SCHEMBL5437478 | 0.80 | ABCG2 (0.48) | EGFRGRM4PIK3CAPIK3CGTGFBR1 | |
| SCHEMBL5440546 | 0.79 | EGFR (0.45) | EGFRGRM4TGFBR1ERBB2ERBB4 | |
| SCHEMBL5446058 | 0.79 | EGFR (0.45) | EGFRGRM4KDRTGFBR1ERBB2 | |
| SCHEMBL5446070 | 0.76 | TGFBR1 (0.46) | EGFRGRM4PIK3CAPIK3CGKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007511570-A | — | — | 2007-05-10 | — | — | JP | claimed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | claimed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | claimed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | ALK, NPR3, CBR3 | EGFR 1404/4885GRM4 3283/4885EPHX2 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.